search
Back to results

Trial of Naproxen to Evaluate Various Methods of Measuring Analgesic Effect in Osteoarthritis Pain of the Knee

Primary Purpose

Osteoarthritis, Knee

Status
Unknown status
Phase
Not Applicable
Locations
United States
Study Type
Interventional
Intervention
Naproxen
Placebo
Sponsored by
Analgesic Solutions
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Osteoarthritis, Knee focused on measuring osteoarthritis, knee, Naproxen

Eligibility Criteria

21 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  1. Subject able to read, comprehend and sign written Informed Consent Form
  2. Subject is 21 years old or older
  3. If female, should be post-menopausal or has negative urine test
  4. Subject has some degree of target joint pain for the last 3 months
  5. Subject has to have 3 out of six:

    ( )Age > 50 ( )Morning stiffness < 30 minutes ( )Crepitus on active motion ( )Bony enlargement ( )No palpable warmth of synovium

  6. Subject had an X-ray of the target knee showing evidence of OA within the past 3 years
  7. Target joint does not contain any type of orthopedic and/or prosthetic device
  8. Subject is ambulatory
  9. Subject is in good general medical and psychological health, and is capable of completing study assessments and procedures.

Exclusion Criteria:

  1. Subject had an x-ray of the target knee showing Kellgren-Lawrence grade 4
  2. Subject has any pain syndrome that has the potential to confound the assessment of the target knee.
  3. the subject has a documented history of an adverse reaction to NSAIDs or acetaminophen
  4. Subject is pregnant or breast feeding
  5. Subject has sitting systolic pressure > 180 mmHg or < 90mmHg, and/or a sitting diastolic pressure > 100 mmHg or < 50 mmHg at screening
  6. Subject has mass body index (BMI) > 35 kg/m2.
  7. Subject has a Hospital Anxiety and Depression Scale (HADS) score > 12 on either subscale or has an established history of major depressive disorder not controlled with medication
  8. Subject has had an introduction of physiotherapy, acupuncture, or transcutaneous electrical nerve stimulation within 4 weeks before screening, or has no stable regimen of these modalities.
  9. Subject has a clinically significant abnormalities in clinical chemistry, hematology, coagulation, or urinalysis.
  10. Subject has a significant history or renal impairment
  11. Subject has a positive urine drug screen for alcohol, illicit drugs or nonprescribed controlled substances
  12. Subject has dermatological lesions of the target knee or ipsilateral elbow at the time of screening.
  13. Subject is unable to discontinue all formulations of prior analgesics
  14. Subject has received any investigational drug within 30 days prior to screening
  15. Subject has a history of active peptic ulceration, gastrointestinal bleeding, esophageal, or gastric or duodenal ulcer within 3 months of screening
  16. Subject has had a surgical intervention for any pain within 3 months of screening or plans for surgical intervention while in the study
  17. Subject has a documented history of inflammatory arthritis, including rheumatoid arthritis.
  18. Subject has received local corticosteroid injections, viscosupplementation, or arthrocentesis in the target joint within 3 months of screening
  19. Subject has received oral or intramuscular corticosteroids within the past 30 days
  20. Subject is involved in an ongoing or settled worker's compensation claim, disability, or litigation related to any pain problem
  21. Subject had used opioids for pain more than 4 days in the week preceding screening
  22. Subject has a history of alcohol or drug abuse/dependence/misuse within 2 years of screening
  23. Subject has history of acute coronary syndrome, ischemic or hemorrhagic stroke, transient ischemic attack, or previous revascularization procedure to coronary or peripheral vasculature, or has a history of congestive heart failure within 5 years of screening
  24. Subject has had axillary lymph nodes removed bilaterally
  25. Subject has a disease-related or iatrogenic coagulopathy, or had been diagnosed with thrombocytopenia or a functional platelet disorder
  26. The subject is currently on an aromatase inhibitor.
  27. Subject has a history of any condition that, in the Investigator's opinion, precludes participation in the study

Sites / Locations

  • Analgesic SolutionsRecruiting

Arms of the Study

Arm 1

Arm 2

Arm Type

Active Comparator

Sham Comparator

Arm Label

Naproxen

Placebo

Arm Description

Outcomes

Primary Outcome Measures

Efficacy of naproxen vs. placebo
Efficacy of naproxen VS placebo will be analyzed by efficacy end-points of within-subject difference. Efficacy evaluations will include: In-clinic pain intensity NRS (24-hour recall) WOMAC: pain subscale, stiffness subscale, function subscale, and total scores Daily actiwatch pain intensity In-clinic pain intensity NRS for curent pain at rest and after exercise Thermal pain matching at rest and after exercise PGIC (Patient's Global Impression of Change) Subject treatment reference
Safety
Safety of Naproxen VS Placebo Safety evaluations will include: Adverse events (AEs)and serious AEs (SAEs) Vital signs Clinical Laboratories Concomitant medications

Secondary Outcome Measures

Full Information

First Posted
February 21, 2012
Last Updated
March 21, 2012
Sponsor
Analgesic Solutions
search

1. Study Identification

Unique Protocol Identification Number
NCT01557816
Brief Title
Trial of Naproxen to Evaluate Various Methods of Measuring Analgesic Effect in Osteoarthritis Pain of the Knee
Official Title
A Randomized, Double-Blind, Placebo-controlled Cross-over, Exploratory Trial of Naproxen to Evaluate Methods of Measuring Analgesic Effect in Osteoarthritis Pain of the Knee
Study Type
Interventional

2. Study Status

Record Verification Date
February 2012
Overall Recruitment Status
Unknown status
Study Start Date
December 2011 (undefined)
Primary Completion Date
June 2012 (Anticipated)
Study Completion Date
June 2012 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Analgesic Solutions

4. Oversight

Data Monitoring Committee
Yes

5. Study Description

Brief Summary
This study aims to evaluate various methods of measuring pain relief in subjects who have chronic OA of the knee. After a 1 week of wash-out from existing therapy, subjects will be treated in a blinded fashion for 1 week with either naproxen (3 days at 250 mg twice a day followed by 4 days at 500 mg twice a day) or placebo. After the first week of treatment, subjects will have another week of wash-out followed by a second period of 1 week of the alternate treatment. Subjects will not be allowed to use oral non-steroidal anti-inflammatory drugs (NSAIDs) or other oral analgesics, or topical medications on their target knees during the study. Acetaminophen will be allowed as a rescue medication.
Detailed Description
This study aims to evaluate various methods of measuring pain relief in osteoarthritis (OA) of the knee. The duration of the study will be up to 5 weeks. Eligible subjects will have chronic OA of the knee. After meeting initial entry criteria and prior to randomization, there will be a 1 week wash-out from existing therapy. Subjects will then be treated in a blinded fashion for 1 week with either naproxen (3 days at 250 mg twice a day followed by 4 days at 500 mg twice a day) or placebo. After the first week of treatment, subjects will have a week of wash-out followed by a second period of 1 week of the alternate treatment. Subjects will not be allowed to use oral non-steroidal anti-inflammatory drugs (NSAIDs) or other oral analgesics, nor will they be allowed to use topical medications on their target knees during the study. Acetaminophen will be allowed as a rescue medication (as needed up to 2 g/day)but subjects will be told not to take acetaminophen at least 12 hours before study visits. Seventy (70) subjects will be randomized to ensure that 60 subjects complete both treatment arms.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Osteoarthritis, Knee
Keywords
osteoarthritis, knee, Naproxen

7. Study Design

Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Crossover Assignment
Masking
ParticipantCare ProviderInvestigatorOutcomes Assessor
Allocation
Randomized
Enrollment
70 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
Naproxen
Arm Type
Active Comparator
Arm Title
Placebo
Arm Type
Sham Comparator
Intervention Type
Drug
Intervention Name(s)
Naproxen
Other Intervention Name(s)
Aleve, Naprosyn
Intervention Description
Naproxen for 7 days (3 days at 250 mg BID followed by 4 days at 500 mg BID) during either of the 2 treatment periods.
Intervention Type
Drug
Intervention Name(s)
Placebo
Other Intervention Name(s)
Sugar pill
Intervention Description
Placebo for seven days given BID during either of the 2 treatment periods.
Primary Outcome Measure Information:
Title
Efficacy of naproxen vs. placebo
Description
Efficacy of naproxen VS placebo will be analyzed by efficacy end-points of within-subject difference. Efficacy evaluations will include: In-clinic pain intensity NRS (24-hour recall) WOMAC: pain subscale, stiffness subscale, function subscale, and total scores Daily actiwatch pain intensity In-clinic pain intensity NRS for curent pain at rest and after exercise Thermal pain matching at rest and after exercise PGIC (Patient's Global Impression of Change) Subject treatment reference
Time Frame
5 weeks
Title
Safety
Description
Safety of Naproxen VS Placebo Safety evaluations will include: Adverse events (AEs)and serious AEs (SAEs) Vital signs Clinical Laboratories Concomitant medications
Time Frame
5 weeks

10. Eligibility

Sex
All
Minimum Age & Unit of Time
21 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Subject able to read, comprehend and sign written Informed Consent Form Subject is 21 years old or older If female, should be post-menopausal or has negative urine test Subject has some degree of target joint pain for the last 3 months Subject has to have 3 out of six: ( )Age > 50 ( )Morning stiffness < 30 minutes ( )Crepitus on active motion ( )Bony enlargement ( )No palpable warmth of synovium Subject had an X-ray of the target knee showing evidence of OA within the past 3 years Target joint does not contain any type of orthopedic and/or prosthetic device Subject is ambulatory Subject is in good general medical and psychological health, and is capable of completing study assessments and procedures. Exclusion Criteria: Subject had an x-ray of the target knee showing Kellgren-Lawrence grade 4 Subject has any pain syndrome that has the potential to confound the assessment of the target knee. the subject has a documented history of an adverse reaction to NSAIDs or acetaminophen Subject is pregnant or breast feeding Subject has sitting systolic pressure > 180 mmHg or < 90mmHg, and/or a sitting diastolic pressure > 100 mmHg or < 50 mmHg at screening Subject has mass body index (BMI) > 35 kg/m2. Subject has a Hospital Anxiety and Depression Scale (HADS) score > 12 on either subscale or has an established history of major depressive disorder not controlled with medication Subject has had an introduction of physiotherapy, acupuncture, or transcutaneous electrical nerve stimulation within 4 weeks before screening, or has no stable regimen of these modalities. Subject has a clinically significant abnormalities in clinical chemistry, hematology, coagulation, or urinalysis. Subject has a significant history or renal impairment Subject has a positive urine drug screen for alcohol, illicit drugs or nonprescribed controlled substances Subject has dermatological lesions of the target knee or ipsilateral elbow at the time of screening. Subject is unable to discontinue all formulations of prior analgesics Subject has received any investigational drug within 30 days prior to screening Subject has a history of active peptic ulceration, gastrointestinal bleeding, esophageal, or gastric or duodenal ulcer within 3 months of screening Subject has had a surgical intervention for any pain within 3 months of screening or plans for surgical intervention while in the study Subject has a documented history of inflammatory arthritis, including rheumatoid arthritis. Subject has received local corticosteroid injections, viscosupplementation, or arthrocentesis in the target joint within 3 months of screening Subject has received oral or intramuscular corticosteroids within the past 30 days Subject is involved in an ongoing or settled worker's compensation claim, disability, or litigation related to any pain problem Subject had used opioids for pain more than 4 days in the week preceding screening Subject has a history of alcohol or drug abuse/dependence/misuse within 2 years of screening Subject has history of acute coronary syndrome, ischemic or hemorrhagic stroke, transient ischemic attack, or previous revascularization procedure to coronary or peripheral vasculature, or has a history of congestive heart failure within 5 years of screening Subject has had axillary lymph nodes removed bilaterally Subject has a disease-related or iatrogenic coagulopathy, or had been diagnosed with thrombocytopenia or a functional platelet disorder The subject is currently on an aromatase inhibitor. Subject has a history of any condition that, in the Investigator's opinion, precludes participation in the study
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Stephen Wright, M.D.
Phone
781-444-9605
Ext
101
Email
swright@analgesicsolutions.com
First Name & Middle Initial & Last Name or Official Title & Degree
Pura Requintina, Ph.D.
Phone
781-444-9605
Ext
121
Email
prequintina@analgesicsolutions.com
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Stephen Wright, MD
Organizational Affiliation
Analgesic Solutions
Official's Role
Principal Investigator
Facility Information:
Facility Name
Analgesic Solutions
City
Natick
State/Province
Massachusetts
ZIP/Postal Code
01760
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Stephen Wright, MD
Phone
781-444-9605
Ext
101
Email
swright@analgesicsolutions.com
First Name & Middle Initial & Last Name & Degree
Pura Requintina, Ph.D.
Phone
781-444-9605
Ext
121
Email
prequintina@analgesicsolutions.com
First Name & Middle Initial & Last Name & Degree
Stephen Wright, MD

12. IPD Sharing Statement

Learn more about this trial

Trial of Naproxen to Evaluate Various Methods of Measuring Analgesic Effect in Osteoarthritis Pain of the Knee

We'll reach out to this number within 24 hrs